Bristol-Myers Squibb (NYSE:BMY) Position Lessened by Fisher Asset Management LLC

Fisher Asset Management LLC lowered its position in Bristol-Myers Squibb (NYSE:BMY) by 0.7% during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 226,480 shares of the biopharmaceutical company’s stock after selling 1,518 shares during the quarter. Fisher Asset Management LLC’s holdings in Bristol-Myers Squibb were worth $11,718,000 at the end of the most recent quarter.

Several other hedge funds also recently bought and sold shares of the company. Daiwa Securities Group Inc. grew its stake in shares of Bristol-Myers Squibb by 31.1% in the 3rd quarter. Daiwa Securities Group Inc. now owns 330,191 shares of the biopharmaceutical company’s stock valued at $17,084,000 after buying an additional 78,309 shares in the last quarter. Pekin Hardy Strauss Inc. grew its position in Bristol-Myers Squibb by 13.9% in the third quarter. Pekin Hardy Strauss Inc. now owns 29,552 shares of the biopharmaceutical company’s stock worth $1,529,000 after acquiring an additional 3,600 shares in the last quarter. Summit Trail Advisors LLC increased its stake in shares of Bristol-Myers Squibb by 1.8% during the 3rd quarter. Summit Trail Advisors LLC now owns 49,473 shares of the biopharmaceutical company’s stock worth $2,560,000 after purchasing an additional 894 shares during the last quarter. SevenBridge Financial Group LLC raised its holdings in shares of Bristol-Myers Squibb by 2.4% during the 3rd quarter. SevenBridge Financial Group LLC now owns 46,991 shares of the biopharmaceutical company’s stock valued at $2,431,000 after purchasing an additional 1,093 shares in the last quarter. Finally, Centaurus Financial Inc. boosted its holdings in Bristol-Myers Squibb by 21.3% in the third quarter. Centaurus Financial Inc. now owns 10,919 shares of the biopharmaceutical company’s stock worth $565,000 after purchasing an additional 1,920 shares in the last quarter. 76.41% of the stock is owned by institutional investors and hedge funds.

Insider Transactions at Bristol-Myers Squibb

In other Bristol-Myers Squibb news, SVP Phil M. Holzer sold 700 shares of the company’s stock in a transaction dated Monday, November 4th. The shares were sold at an average price of $55.62, for a total transaction of $38,934.00. Following the sale, the senior vice president now directly owns 11,760 shares of the company’s stock, valued at approximately $654,091.20. This represents a 5.62 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, EVP Samit Hirawat bought 1,830 shares of the business’s stock in a transaction dated Friday, November 1st. The stock was purchased at an average price of $54.67 per share, with a total value of $100,046.10. Following the purchase, the executive vice president now directly owns 62,109 shares of the company’s stock, valued at $3,395,499.03. The trade was a 3.04 % increase in their position. The disclosure for this purchase can be found here. 0.09% of the stock is currently owned by insiders.

Analyst Ratings Changes

Several equities analysts have weighed in on BMY shares. Wolfe Research started coverage on Bristol-Myers Squibb in a report on Friday, November 15th. They set a “peer perform” rating on the stock. Citigroup boosted their target price on Bristol-Myers Squibb from $55.00 to $60.00 and gave the stock a “neutral” rating in a report on Tuesday, November 12th. Leerink Partnrs upgraded Bristol-Myers Squibb from a “hold” rating to a “strong-buy” rating in a report on Tuesday, November 12th. BMO Capital Markets upped their price objective on shares of Bristol-Myers Squibb from $57.00 to $61.00 and gave the stock a “market perform” rating in a report on Tuesday, November 12th. Finally, Morgan Stanley lifted their target price on shares of Bristol-Myers Squibb from $36.00 to $39.00 and gave the stock an “underweight” rating in a report on Tuesday, November 12th. Two investment analysts have rated the stock with a sell rating, fourteen have assigned a hold rating, two have given a buy rating and three have given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, Bristol-Myers Squibb currently has a consensus rating of “Hold” and a consensus price target of $54.07.

Bristol-Myers Squibb Stock Performance

Shares of NYSE BMY opened at $59.27 on Thursday. The firm has a market capitalization of $120.21 billion, a price-to-earnings ratio of -16.51, a PEG ratio of 15.77 and a beta of 0.44. Bristol-Myers Squibb has a one year low of $39.35 and a one year high of $61.08. The business has a fifty day simple moving average of $54.21 and a 200 day simple moving average of $48.05. The company has a current ratio of 1.24, a quick ratio of 1.09 and a debt-to-equity ratio of 2.83.

Bristol-Myers Squibb (NYSE:BMY) last announced its quarterly earnings data on Thursday, October 31st. The biopharmaceutical company reported $1.80 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.49 by $0.31. Bristol-Myers Squibb had a negative net margin of 15.30% and a positive return on equity of 11.94%. The company had revenue of $11.89 billion during the quarter, compared to analysts’ expectations of $11.26 billion. During the same quarter in the prior year, the company posted $2.00 EPS. The business’s revenue was up 8.4% on a year-over-year basis. Sell-side analysts expect that Bristol-Myers Squibb will post 0.93 EPS for the current year.

Bristol-Myers Squibb Announces Dividend

The business also recently disclosed a quarterly dividend, which was paid on Friday, November 1st. Stockholders of record on Friday, October 4th were paid a $0.60 dividend. The ex-dividend date of this dividend was Friday, October 4th. This represents a $2.40 annualized dividend and a dividend yield of 4.05%. Bristol-Myers Squibb’s dividend payout ratio is currently -66.85%.

Bristol-Myers Squibb Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.